Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.
The fatal disease caused by Bacillus anthracis is preventable with a prophylactic vaccine. The currently available anthrax vaccine requires a lengthy immunization schedule, and simpler and more immunogenic options for protection against anthrax are a priority for development. In this report we descr...
Main Authors: | Bruce K Brown, Josephine Cox, Anita Gillis, Thomas C VanCott, Mary Marovich, Mark Milazzo, Tanya Santelli Antonille, Lindsay Wieczorek, Kelly T McKee, Karen Metcalfe, Raburn M Mallory, Deborah Birx, Victoria R Polonis, Merlin L Robb |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-11-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2974626?pdf=render |
Similar Items
-
Ghost at the machine : Internet addiction and compulsive computer use
by: VanCott, Rachel Diane
Published: (2009) -
Characterization of the UK anthrax vaccine and human immunogenicity
by: Tapasvi Modi, et al.
Published: (2021-03-01) -
Germline landscape of RPA1, RPA2 and RPA3 variants in pediatric malignancies: identification of RPA1 as a novel cancer predisposition candidate gene
by: Richa Sharma, et al.
Published: (2023-10-01) -
Overview of RPA technologies
by: A. Troianovska, et al.
Published: (2023-12-01) -
What Is Anthrax?
by: William A. Bower, et al.
Published: (2022-06-01)